Topigen Pharmaceuticals Inc.

Topigen Pharmaceuticals is a biotechnology company that is focused on the scientific research and development of therapeutic drugs. It develops treatments for respiratory disorders, including asthma and chronic obstructive pulmonary disease.

Topigen Pharmaceuticals offers TPI ASM8, a drug that is developed for the management of moderate to severe asthma; and TPI 1100, a drug that is developed for the chronic obstructive pulmonary disease.

Topigen Pharmaceuticals was acquired by Pharmaxis in January 2010.

Topigen Pharmaceuticals was founded in 2000 and is based in Montreal, Quebec.